Crescent Grove Advisors’s Biogen BIIB Stock Holding History

Crescent Grove Advisors’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-2,000	Closed	-$408K	–	260
2022 Q2	$408K	Hold	2,000	–	–	0.04%	176
2022 Q1	$421K	Hold	2,000	–	–	0.04%	185
2021 Q4	$480K	Buy	2,000 +444	+29%	+$114K	0.05%	170
2021 Q3	$440K	Hold	1,556	–	–	0.05%	169
2021 Q2	$539K	Buy	1,556 +56	+4%	+$17K	0.06%	146
2021 Q1	$420K	Hold	1,500	–	–	0.05%	139
2020 Q4	$367K	Hold	1,500	–	–	0.05%	135
2020 Q3	$426K	Hold	1,500	–	–	0.08%	112
2020 Q2	$401K	Hold	1,500	–	–	0.08%	101
2020 Q1	$475K	Hold	1,500	–	–	0.11%	79
2019 Q4	$445K	Buy	1,500 +500	+50%	+$139K	0.08%	100
2019 Q3	$233K	Hold	1,000	–	–	0.04%	139
2019 Q2	$234K	Sell	1,000 -50	-5%	-$11.5K	0.04%	137
2019 Q1	$248K	Buy	+1,050	New	+$331K	0.05%	128

Other funds holding BIIB

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Crescent Grove Advisors's BIIB Position: Q3 2022 in Review

Crescent Grove Advisors sold out of Biogen (BIIB) in Q3 2022, closing a stake of 2,000 shares — an estimated $408K sold.

Crescent Grove Advisors first reported a position in BIIB in Q1 2019 and held it in 14 quarters. The position peaked at $539K in Q2 2021. 985 funds tracked by Wall St. Rank hold BIIB as of Q3 2022.

Crescent Grove Advisors reported no remaining Biogen position as of Q3 2022 after selling out during the quarter.
Crescent Grove Advisors sold 2,000 Biogen shares in Q3 2022, an estimated $408K.
Crescent Grove Advisors first reported a position in Biogen in Q1 2019 and held it in 14 quarters.
Crescent Grove Advisors's Biogen position peaked at $539K in Q2 2021.
985 funds tracked by Wall St. Rank held Biogen as of Q3 2022.

Based on Crescent Grove Advisors's 13F filing for Q3 2022, filed 8 Nov 2022.